10 September 2024

Congratulations to our Pathology team for performing the 100th solid tumour next-generation sequencing (NGS) last week!

NGS panels refer to a DNA sequencing test which examines the DNA from a list of genes that are commonly mutated in cancers. Austin Health’s Pathology has been testing a variety of solid tumours and haematological malignancies on customised NGS panels since November 2020.

The test identifies genetic mutations in cancer that can be important for diagnosing and tailoring patient’s treatment, particularly where there are drugs acting against the mutation. Some mutations are very suggestive of a particular cancer type which can assist pathologists in diagnosis. Other mutations can be associated with either a better or worse outcome for a particular cancer, which may also guide treatment.

Last week the 100th solid tumour NGS run was performed and reported by our team of dedicated scientists and pathologists from both the molecular and anatomical pathology labs.

“In reaching this milestone there is a sense that we are working well as a laboratory to assist clinical doctors treat patients with cancer, but we are also intent on enhancing existing tests as new technology becomes available,” shares Jonathan Clark, Pathologist.

He continues, “The solid tumour NGS panel is predominantly used in the context of melanoma and carcinomas of the lung, colon and endometrium but with expanded NGS panels in the process of being validated the molecular service will soon broaden its testing capabilities. The new tests will become available the next year.”

This milestone underscores our commitment to delivering high-quality patient care by leveraging advanced genetic testing to provide precise diagnoses and tailored treatments; and the Pathology team celebrated with doughnuts!

Congratulations once again to our Pathology team on this amazing accomplishment!